UK Prostate Cancer Screening Trial: First Men Tested in Landmark Study

The first men have been tested as part of the £42 million TRANSFORM trial, a landmark UK study investigating the future of prostate cancer screening. Jaroslaw Galik, 55, from London, was among the initial participants who underwent a combination of PSA blood tests, prompt MRI scans, and genetic spit tests at the InHealth community diagnostic centre in Ealing, west London.

The trial, co-funded by Prostate Cancer UK and the National Institute for Health and Care Research (NIHR), aims to determine the most effective methods for screening men for prostate cancer, with the ultimate goal of establishing a population-wide screening program. Currently, the UK lacks a national screening program for the disease, despite it being the most common cancer in men in the UK.

The launch of TRANSFORM comes as the UK National Screening Committee (UKNSC) prepares to publish its final guidance this week on prostate cancer screening. A draft recommendation last year advised against population-wide screening using the prostate specific antigen (PSA) test, citing concerns that it “is likely to cause more harm than good.” The committee did recommend screening men with BRCA1 and BRCA2 genetic mutations, who are at significantly higher risk, every two years between the ages of 45 and 61.

Health Secretary Wes Streeting has expressed surprise at the draft recommendation, emphasizing that any final decision must be “based on science and evidence, not on politics.” The debate surrounding the PSA test centers on its reliability; experts note that a high PSA level does not always indicate cancer, and some men with cancer have normal PSA results. Concerns also exist that positive results may lead to unnecessary treatment for slow-growing or harmless tumors, potentially causing side effects like incontinence and erectile dysfunction.

However, proponents of wider testing argue that current evidence supports it and have urged the UKNSC to reconsider. The committee has agreed to review any new evidence generated by the TRANSFORM trial. Laura Kerby, chief executive of Prostate Cancer UK, stated, “Men across the country are crying out for a screening programme and we’re committed to building a future where every man gets that chance.”

The TRANSFORM trial will initially compare new screening techniques against current NHS methods. The most promising approaches will then be tested in a larger group of up to 300,000 men. A key focus of the trial is to gather more data relating to black men, who are at double the risk of developing and dying from prostate cancer, with a goal of ensuring one in ten participants are from this demographic. Currently, the UKNSC does not recommend specific screening for black men due to a lack of data.

Mr. Galik, one of the first participants, explained his motivation for joining the trial: “When the letter about Transform came through, I realised this was a straightforward way to check my own risk while also contributing to something bigger. To think that just by taking a couple of tests I could be helping to finally receive to screening and save thousands of lives is incredible.”

Professor Lucy Chappell, chief scientific adviser at the Department of Health and chief executive officer of the NIHR, described the trial as a “huge moment,” stating that it “aims to tackle one of the biggest killers as part of the shift from sickness to prevention.” She also highlighted the trial’s focus on men at highest risk, particularly black men, and the commitment to ensuring meaningful participation in research across all segments of society.

Mr. Streeting added, “Transform is the most ambitious prostate cancer research programme in a generation and I’m proud the Government is backing it. The evidence it generates will be crucial in shaping how we screen for this disease for decades to come.”